Background
==========

Vancomycin remains the antibiotic of choice for treating serious infection with methicillin-resistant *Staphylococcus aureus* (MRSA) and other serious Gram-positive infections despite its continuous use for over half a century.[@b1-idr-9-087],[@b2-idr-9-087] However, some have called into question "how long vancomycin may remain an effective therapy".[@b3-idr-9-087],[@b4-idr-9-087] In recent years, there have been a number of new agents licensed by the US Food and Drug Administration to treat resistant infection with Gram-positive bacteria, including MRSA; however, it is essential to reserve these agents for when vancomycin is no longer effective.[@b5-idr-9-087], [@b6-idr-9-087]

Prudent management of the way in which vancomycin is used in therapy is by prompt identification of the organism and testing of antibiotic susceptibility, which, along with optimizing dosing and serum concentration monitoring, may help ensure that vancomycin is not abandoned prematurely.[@b7-idr-9-087] There are a number of methods used to determine minimum inhibitory concentration (MIC); however, broth microdilution (BMD) remains the gold standard.[@b8-idr-9-087] The MIC along with vancomycin exposure measured as area under the concentration curve is the key pharmacokinetic--pharmacodynamic index used to optimize bacterial killing and clinical outcomes with vancomycin therapy.[@b9-idr-9-087],[@b10-idr-9-087] An area under the concentration curve/MIC index target of 400 mg/L × hour is recommended for contemporary vancomycin dosing.[@b11-idr-9-087] In the mid-2000s, the US Clinical Laboratory Standards Institute (CLSI) redefined the vancomycin MIC susceptibility breakpoint for *S. aureus* to ≤2 µg/mL.[@b12-idr-9-087] However, since that time, there have been a number of individual studies that have demonstrated associations between isolates with vancomycin MIC in the susceptible range and patient outcomes.[@b13-idr-9-087] Varying methods for determining MIC have been used in these studies, which makes extrapolation of results to routine clinical management challenging. Important consideration must be given to the method used to determine MIC, and decisions for treatment should be based upon the optimal cutoff points for the various methods. A meta-analysis of 14 papers with 2,439 patients with susceptible MRSA infection clearly defined high vancomycin MIC as ≥1 µg/mL by BMD and ≥1.5 µg/mL by *E*-test. This meta-analysis, which included patients with bloodstream and nonbloodstream infection, found a treatment failure risk ratio of 1.40 (95% confidence interval =1.15--1.71) and overall mortality risk ratio of 1.42 (confidence interval =1.08--1.87) for those with high vancomycin MIC.[@b14-idr-9-087]

Although BMD remains the gold standard for measuring vancomycin MIC, this method is time consuming, labor intensive, and requires a high level of skill for consistent results. Alternative methodologies to determine vancomycin MIC such as the automated VITEK^®^ 2 (BioMérieux Inc, Durham NC, USA) and gradient diffusion *E*-test are frequently used in diagnostic laboratories; however, these methods produce varying results in comparison to each other and to BMD.[@b15-idr-9-087]

Inappropriate interpretation and overestimation of the MIC may cause unnecessary use of other agents when vancomycin would still be effective. Assessing the diagnostic accuracy of commonly used MIC methods compared against BMD would assist in meaningful interpretation of MIC values from each method and application of this information to treatment. Unnecessary abandonment of vancomycin for newer antibiotics in patients with MRSA infection with higher yet susceptible MICs (≥1 and ≤2 µg/mL) will potentially promote the emergence of resistance to these agents. Furthermore, the strength of the association among the vancomycin method, MIC, and MRSA phenotype is unclear.

The aim of this study was to measure the diagnostic accuracy of *E*-test and VITEK^®^ 2 vancomycin MIC determination for clinical MRSA isolates compared against a BMD standard. A secondary aim was to explore the strength of the association between MIC and MRSA antibiotic resistance phenotype.

Materials and methods
=====================

Study design, data collection, and ethical approval
---------------------------------------------------

MRSA clinical isolates were obtained from hospitalized patients aged ≥18 years during the process of usual care between April 2012 and December 2013. The study was conducted at Flinders Medical Centre, a 550-bed teaching hospital in Adelaide, Australia. The pathology database ULTRA Laboratory Information System, Release 2.5C (Cirdan, Lisburn, Northern Ireland) was used to identify patient isolates during the study period. The study was approved by the Southern Adelaide Clinical Human Research Ethics Committee (approval number 123.12). A waiver of consent was granted with the approval as the participants were not exposed to any risk of harm. The waiver of consent was consistent with the Australian Government National Statement of Ethical Conduct in Human Research 2007.

Susceptibility testing
----------------------

All MRSA isolates were tested to determine the vancomycin MIC. Isolate susceptibility to vancomycin was defined by the CLSI breakpoint of MIC ≤2 µg/mL. Automated VITEK^®^ 2 System Version 05.04 (BioMérieux Inc.) sensitivity testing was performed on fresh isolates during routine processing. Gradient diffusion *E*-test (BioMérieux Inc.) was used according to the manufacturer's instructions. Reading of *E*-test was conducted independently by a senior medical scientist, with the result confirmed by a medical microbiologist; any disagreement was adjudicated by a third reader. BMD was performed using thawed frozen isolates. Frozen isolates were stored (−20°C for 6--12 months) to enable batched processing. Vancomycin hydrochloride (Sigma-Aldrich, St. Louis, MO, USA) was sourced to prepare the stock solution. Susceptibility was tested at vancomycin concentrations 0.25--8.0 µg/mL in twofold dilutions according to the CLSI methodology.[@b16-idr-9-087]

Validation of MIC results obtained using BMD method was performed concurrently using *S. aureus* ATCC 29213 and *Escherichia coli* ATCC 25922 as controls for every set of tests. MICs were determined after a period of 24 hours of incubation at 35°C in oxygen. Reading of BMD was performed independently by a senior medical scientist, a medical microbiologist, and a specialist pharmacist. Where a difference in reading the MIC occurred, a consensus of two readers was required.

MRSA resistance phenotype
-------------------------

Phenotyping was determined from antibiogram testing using VITEK^®^ 2 AST-612 (BioMérieux Inc.). Three distinct phenotypes were recognized. Nonmultiresistant MRSA isolates were defined as those resistant to \<3 non-β-lactam antibiotic classes, while multiresistant MRSA (mMRSA) isolates were defined as those resistant to ≥3 non-β-lactam antibiotic classes.[@b17-idr-9-087] Epidemic MRSA 15 was separately defined by resistance to ciprofloxacin ± erythromycin antibiotic.[@b18-idr-9-087]

### Statistical analysis

Data were stored in Microsoft Excel and were reported using descriptive statistics. Spearman's rho (*ρ*) correlation coefficients were used to assess the strength of the association between the methods used to determine MIC. Specificity, sensitivity, and area under the receiver operating characteristic curve measured as *C*-statistic were used to calculate diagnostic accuracy for VITEK^®^ 2 and *E*-test MIC methods for detecting strains with MIC ≥1 µg/mL by using BMD as the reference MIC value. The *C*-statistic is a measure of discrimination and reports the global test accuracy, ie, for all cutoff points combined. The reference MIC methodology (BMD) and MIC value were selected as they were shown to be independent predictors of poor clinical outcomes.[@b14-idr-9-087],[@b19-idr-9-087] Fisher's exact test was used to assess whether MRSA phenotype was associated with MIC concentrations for each of the three MIC methods. Stata version 14.0 (StataCorp LP, College Station, TX, USA) was used for all statistical analyses.

Results
=======

A total of 148 isolates were obtained from 111 patients during the study period. The clinical isolates were sourced from multiple anatomical sites, with skin and soft tissue and respiratory sites featuring prominently and 10% of isolates being from blood or central nervous system ([Table 1](#t1-idr-9-087){ref-type="table"}). All MRSA isolates, with the exception of one isolate with *E*-test of 3 µg/mL (1 µg/mL by VITEK^®^ 2 and BMD), were susceptible to vancomycin (≤2 µg/mL) by all the three methods. The distribution of MIC values by methodology is shown in [Table 2](#t2-idr-9-087){ref-type="table"}. The percentage of isolates with MIC ≤0.5 µg/mL was 90.5%, 50%, and 28% by BMD, VITEK^®^ 2, and *E*-test, respectively. MIC values ≥1 µg/mL were observed in 9.5% by BMD, 50% by VITEK^®^ 2, and 72% by *E*-test.

Correlation of MIC methodologies
--------------------------------

Spearman's rho (*ρ*) correlation coefficients between the three methods were significant but weak; 0.29 for *E*-test vs VITEK^®^ 2 (*P*=0.003), 0.27 for *E*-test vs BMD (*P*=0.001), and 0.31 for BMD vs VITEK^®^ 2 (*P*=0.002).

The *C*-statistic was weak for both *E*-test (0.5428) and VITEK^®^ 2 (0.5815) ([Table 3](#t3-idr-9-087){ref-type="table"}). Sensitivity and specificity for detection of an MIC ≥1 µg/mL by BMD were calculated for each possible cutoff point for the *E*-test and VITEK^®^ 2 methods ([Table 3](#t3-idr-9-087){ref-type="table"}). The optimum cutoff point for the *E*-test was ≥1.0 µg/mL, with a sensitivity of 0.85 and specificity of 0.29, while the optimum cutoff point for VITEK^®^ 2 was also ≥1.0 µg/mL, with corresponding values of 0.62 and 0.51, respectively.

Breakdown by phenotype
----------------------

There was no significant association between MRSA phenotype and the BMD MICs (*P*=0.15), although it appeared that there were relatively fewer mMRSA phenotypes than expected at BMD =0.25 µg/mL (2.3%), and relatively more mMRSA than expected at BMD =0.75 µg/mL (6.8%) based on observed percentages for both epidemic MRSA 15 and nonmultiresistant MRSA ([Table 4](#t4-idr-9-087){ref-type="table"}). There was a significant association between MRSA phenotype and the VITEK^®^ 2 MIC categories (*P*\<0.001), with a lower than expected percent of mMRSA at VITEK^®^ 2 =0.5 µg/mL (27.3%) and a higher than expected percent of mMRSA at VITEK^®^ 2 =1.0 µg/mL (70.5%) based on the observed percentages for the other two MRSA phenotypes. There was also a significant association between phenotype and the *E*-test MICs (*P*\<0.001), with a lower than expected percent of mMRSA at *E*-test =0.5 µg/mL MICs and 0.75 µg/mL MICs (0%--7%) and a higher than expected percent of mMRSA at *E*-test =1.5 µg/mL and *E*-test =2 µg/mL (39% and 14%) based on the observed percentages for the other two MRSA phenotypes.

Discussion
==========

In this study of MRSA isolates that were susceptible to vancomycin, we found only a weak level of agreement between the accepted gold standard BMD and two commonly used methods to determine vancomycin MIC (VITEK^®^ 2 and *E*-test). This weak agreement is consistent with the findings of other authors.[@b20-idr-9-087] Although some authors have reported that *E*-test does not produce higher MIC than other methods,[@b21-idr-9-087] we found higher *E*-test MIC values than either BMD or VITEK^®^ 2, which concurs with the results of other studies.[@b22-idr-9-087],[@b23-idr-9-087]

Patient outcomes are worse for MRSA infection with susceptible yet higher vancomycin MICs. Van Hal et al[@b24-idr-9-087] in a systematic review of 22 papers on the significance of vancomycin MIC reported that MIC ≥1.5 µg/mL was associated with worse clinical outcomes than those with \<1.5 µg/mL; however, this MIC range was not ascribed to any one MIC method. In this study, we used valid statistical approaches to compare susceptible MIC values that are obtained in routine care from several commonly used methods.

As BMD is acknowledged as the gold standard method for MIC testing, and a BMD MIC ≥1 µg/mL has been associated with poor clinical outcomes,[@b14-idr-9-087],[@b19-idr-9-087] we compared the diagnostic accuracy of VITEK^®^ 2 and *E*-test using BMD ≥1 µg/mL as the defined cutoff point for indicating reduced susceptibility. The value of sensitivity and specificity was assessed at the various *E*-test and VITEK^®^ 2 MIC categories. For the MRSA strains used in this study, the optimum *E*-test and VITEK^®^ 2 cutoff points for detection of reduced susceptibility were achieved at ≥1 µg/mL (*E*-test: sensitivity 0.85, specificity 0.29; VITEK^®^ 2: sensitivity 0.62, specificity 0.51). These cutoff points need confirmation in a larger and more diverse dataset but provide novel and practical guidance toward assessing MIC results obtained from differing methodologies. These findings should prove useful to both diagnosticians and clinicians in evaluating test results for commonly employed MIC methodologies.

In our study, we observed significant variations in vancomycin MIC by phenotype using *E*-test and VITEK^®^ 2, but not with BMD. Specifically, mMRSA strains had higher MIC values than expected. Since mMRSA strains are more likely to be hospital associated, these strains are likely to spread in an environment of higher vancomycin usage than the other "community-acquired" strains. It is unclear why these differences were not detected by BMD, but the clustering of BMD MICs at 0.5 µg/mL may have limited the ability to detect strain differences.

Guidance on treatment of MRSA infection is based on clinical response to vancomycin rather than MIC.[@b25-idr-9-087] However, if vancomycin MIC is a determinant of antibiotic selection, our findings provide useful guidance to better understanding of MIC results obtained through reference and routine laboratory methods.

The main limitations of our study were that the clinical isolates were obtained from a single geographical region (hospital catchment) and that there were also a relatively small number of isolates which were all in the susceptible range.

Conclusion
==========

The level of agreement between MIC determination by BMD, *E*-test, and VITEK^®^ 2 was relatively weak. The estimated sensitivity and specificity of the methods provide guidance on the best MIC cutoff points to use to interpret the results of each method. This permits more objective evaluation of test results obtained from routine methods and selection of vancomycin when appropriate.
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###### 

Anatomical region clinical isolate obtained

  Specimen site          n     \%
  ---------------------- ----- ------
  Skin and soft tissue   94    63.5
  Respiratory            26    17.6
  Blood/CSF              15    10.1
  Sterile body cavity    8     5.4
  Urine                  3     2.0
  Other                  2     1.4
  Total                  148   100

**Abbreviation:** CSF, cerebrospinal fluid.

###### 

Distribution of vancomycin minimum inhibitory concentrations (MICs) by three methods in 148 clinical isolates

  -------------------------------------------------------------------------------------------------------------------------
  MIC method   0.25   0.38   0.5                                           0.75   1    1.5   2     3     All   MIC range\
                                                                                                               (µg/mL)
  ------------ ------ ------ --------------------------------------------- ------ ---- ----- ----- ----- ----- ------------
  *E*-test     N/A    3      17                                            21     54   41    11    1     148   0.38--3

  VITEK^®^ 2   N/A    N/A    74[a](#tfn2-idr-9-087){ref-type="table-fn"}   N/A    72   N/A   2     N/A   148   ≤0.5--2

  BMD          18     N/A    111                                           5      14   N/A   N/A   N/A   148   0.25--1
  -------------------------------------------------------------------------------------------------------------------------

**Note:**

Lowest dilution reported by VITEK^®^ 2 is ≤0.5 µg/mL.

**Abbreviations:** BMD, broth microdilution; N/A, not applicable.

###### 

Sensitivity and specificity of *E*-test and VITEK^®^ 2 for detection of a minimum inhibitory concentration (MIC) ≥1 µg/mL by broth microdilution (BMD)

  MIC method (µg/mL)   Sensitivity   Specificity   *C*-statistic
  -------------------- ------------- ------------- ---------------
  E-test                                           0.54
  Cutoff point                                     
  ≥0.38                1.00          0.0           
  ≥0.5                 1.00          0.02          
  ≥0.75                1.00          0.15          
  ≥1.0                 0.85          0.29          
  ≥1.5                 0.31          0.64          
  ≥2                   0.08          0.93          
  ≥3                   0.08          1.00          
  VITEK^®^ 2                                       0.58
  Cutoff point                                     
  ≥0.5                 1.00          0.00          
  ≥1.0                 0.62          0.51          
  ≥2.0                 0.08          0.99          

###### 

Relationship between vancomycin minimum inhibitory concentration (MIC) by methodology and methicillin-resistant *Staphylococcus aureus* (MRSA) phenotype

  MIC (µg/mL)                         EMRSA-15    mMRSA       nmMRSA      Total
  ----------------------------------- ----------- ----------- ----------- ------------
  Broth microdilution method, n (%)                                       
  0.25                                5 (15.2)    1 (2.3)     12 (17.4)   18 (12.3)
  0.5                                 25 (75.8)   36 (81.8)   50 (72.5)   111 (76.0)
  0.75                                0 (0.0)     3 (6.8)     2 (2.9)     5 (3.4)
  1.0                                 3 (9.1)     4 (9.1)     5 (7.3)     12 (8.2)
  Total                               33 (100)    44 (100)    69 (100)    146 (100)
  VITEK^®^ 2 method, n (%)                                                
  0.5                                 28 (84.9)   12 (27.3)   33 (47.8)   73 (50)
  1.0                                 5 (15.2)    31 (70.5)   35 (50.7)   71 (48.6)
  2.0                                 0.00        1 (2.3)     1 (1.5)     2 (1.4)
  Total                               33 (100)    44 (100)    69 (100)    146 (100)
  *E*-test method, n (%)                                                  
  0.38                                0 (0.0)     0 (0.0)     3 (4.4)     3 (2.1)
  0.5                                 5 (15.2)    0 (0.0)     12 (17.4)   17 (11.6)
  0.75                                8 (24.2)    3 (6.8)     10 (14.5)   21 (14.4)
  1.0                                 16 (48.5)   17 (38.6)   20 (29.0)   53 (36.3)
  1.5                                 3 (9.09)    17 (38.6)   21 (30.4)   41 (28.1)
  2.0                                 1 (3.03)    6 (13.6)    3 (4.4)     10 (6.9)
  3.0                                 0 (0.0)     1 (2.3)     0 (0.0)     1 (0.7)
  Total                               33 (100)    44 (100)    69 (100)    146 (100)

**Note:** n=146 (two isolates were unable to be sourced when phenotyping performed).

**Abbreviations:** EMRSA-15, epidemic MRSA; mMRSA, multiresistant MRSA; nmMRSA, nonmultiresistant MRSA.
